In the therapeutic model, the mice first were subcutaneously (s.c.)injected with B16-MUC1 melanoma cells on day 0, and then seven days after the tumor challenge, the mice were immunized with the vaccine five or eight times at 7-day intervals, as shown in Figure 6A. On the fifth day after the final immunization, the mice were euthanized; the tumors were removed, and the MUC1-specific antibody levels, lymphocyte proliferation, IFN-γ secretion from lymphocytes, and CTL cytotoxicity were measured. This evidence concerns the gene IFNG and melanoma.